• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed

    2/16/21 10:03:59 AM ET
    $PHIO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $PHIO alert in real time by email
    SC 13G/A 1 tm216476d42_sc13ga.htm SC 13G/A

     

    CUSIP No: 71880W303

     

     

     

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

     

    SCHEDULE 13G

     

    (Rule 13d-102)

     

    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT

    TO § 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED

    PURSUANT TO § 240.13d-2.

     

    (Amendment No. 1)*

     

    Phio Pharmaceuticals Corp.

    (Name of Issuer)

     

    Common Stock, $0.0001 par value per share

    (Title of Class of Securities)

     

    71880W303
    (CUSIP Number)

     

    December 31, 2020

    (Date of Event Which Requires Filing of this statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ¨ Rule 13d-1(b)

    x Rule 13d-1(c)

    ¨ Rule 13d-1(d)

     

     

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

    CUSIP No: 71880W303

     

    (1) NAMES OF REPORTING PERSONS
     
      CVI Investments, Inc.
     
    (2) CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
    (a)     ¨
    (b)     ¨
     
    (3) SEC USE ONLY
     
    (4) CITIZENSHIP OR PLACE OF ORGANIZATION
     
      Cayman Islands
       

    NUMBER OF (5) SOLE VOTING POWER
     
    SHARES 0  
         
    BENEFICIALLY
    (6) SHARED VOTING POWER **
    OWNED BY
      228,896
    EACH
     
    REPORTING (7) SOLE DISPOSITIVE POWER
     
    PERSON WITH 0
         
     
    (8) SHARED DISPOSITIVE POWER **
     
      228,896
       

    (9) AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
      228,896
     
    (10) CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
    ¨
     
    (11) PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
      4.0%
       
    (12) TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
       
      CO
       

    ** Heights Capital Management, Inc. is the investment manager to CVI Investments, Inc. and as such may exercise voting and dispositive power over these shares.

     

     

     

    CUSIP No: 71880W303

     

    (1) NAMES OF REPORTING PERSONS
     
      Heights Capital Management, Inc.
     
    (2) CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
    (a)     ¨
    (b)     ¨
     
    (3) SEC USE ONLY
     
    (4) CITIZENSHIP OR PLACE OF ORGANIZATION
     
      Delaware
       

    NUMBER OF (5) SOLE VOTING POWER
     
    SHARES 0  
         
    BENEFICIALLY
    (6) SHARED VOTING POWER **
    OWNED BY
      228,896
    EACH
     
    REPORTING (7) SOLE DISPOSITIVE POWER
     
    PERSON WITH 0
         
     
    (8) SHARED DISPOSITIVE POWER **
     
      228,896
       

    (9) AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
      228,896
     
    (10) CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
    ¨
     
    (11) PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
      4.0%
       
    (12) TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
       
      CO
       

    ** Heights Capital Management, Inc. is the investment manager to CVI Investments, Inc. and as such may exercise voting and dispositive power over these shares.

     

     

     

    CUSIP No: 71880W303

     

    Item 1.

     

    (a)Name of Issuer

     

    Phio Pharmaceuticals Corp. (the “Company”)

     

    (b)Address of Issuer’s Principal Executive Offices

     

    257 Simarano Drive, Suite 101, Marlborough, Massachusetts 01752

     

    Item 2(a). Name of Person Filing

     

    This statement is filed by the entities listed below, who are collectively referred to herein as “Reporting Persons,” with respect to the shares of common stock of the Company, $0.0001 par value per share (the “Shares”).

     

    (i)CVI Investments, Inc.

     

    (ii)Heights Capital Management, Inc.

     

    Item 2(b). Address of Principal Business Office or, if none, Residence

     

    The address of the principal business office of CVI Investments, Inc. is:

     

    P.O. Box 309GT

    Ugland House

    South Church Street

    George Town

    Grand Cayman

    KY1-1104

    Cayman Islands

     

    The address of the principal business office of Heights Capital Management, Inc. is:

     

    101 California Street, Suite 3250

    San Francisco, California 94111

     

    Item 2(c). Citizenship

     

    Citizenship is set forth in Row 4 of the cover page for each Reporting Person hereto and is incorporated herein by reference for each such Reporting Person.

     

    Item 2(d) Title of Class of Securities

     

    Common stock, $0.0001 par value per share

     

    Item 2(e) CUSIP Number

     

    71880W303

     

     

     

    CUSIP No: 71880W303

     

    Item 3.If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

    (a)¨ Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o).

     

    (b)¨ Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c).

     

    (c)¨ Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c).

     

    (d)¨ Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).

     

    (e)¨ An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);

     

    (f)¨ An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);

     

    (g)¨ A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);

     

    (h)¨ A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

     

    (i)¨ A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

     

    (j)¨ A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J);

     

    (k)¨ Group, in accordance with Rule 13d-1(b)(1)(ii)(K).

     

    If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution: ________________

     

    Item 4.Ownership

     

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

     

    The information required by Items 4(a) – (c) is set forth in Rows 5 – 11 of the cover page for each Reporting Person hereto and is incorporated herein by reference for each such Reporting Person.

     

    The number of Shares reported as beneficially owned consists of Shares issuable upon the exercise of warrants to purchase Shares.

     

    The Company’s Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2020 indicates there were 5,780,592 Shares outstanding as of November 6, 2020.

     

    Heights Capital Management, Inc., which serves as the investment manager to CVI Investments, Inc., may be deemed to be the beneficial owner of all Shares owned by CVI Investments, Inc. Each of the Reporting Persons hereby disclaims any beneficial ownership of any such Shares, except for their pecuniary interest therein.

     

    Item 5. Ownership of Five Percent or Less of a Class

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following: x

     

     

     

    CUSIP No: 71880W303

     

    Item 6. Ownership of More than Five Percent on Behalf of Another Person

     

    Not applicable.

     

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person

     

    Not applicable.

     

    Item 8. Identification and Classification of Members of the Group

     

    Not applicable.

     

    Item 9. Notice of Dissolution of Group

     

    Not applicable.

     

    Item 10. Certification

     

    By signing below each of the undersigned certifies that, to the best of its knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     

     

    CUSIP No: 71880W303

     

    SIGNATURES

     

    After reasonable inquiry and to the best of its knowledge and belief, each of the undersigned certifies that the information with respect to it set forth in this statement is true, complete, and correct.

     

    Dated: February 10, 2021

     

    CVI INVESTMENTS, INC.     HEIGHTS CAPITAL MANAGEMENT, INC.
         
    By: Heights Capital Management, Inc.   By: /s/ Brian Sopinsky
    pursuant to a Limited Power of Attorney, a copy of which was   Name: Brian Sopinsky
    previously filed   Title: Secretary

     

    By: /s/ Brian Sopinsky    
    Name: Brian Sopinsky    
    Title: Secretary    

       

     

     

    CUSIP No: 71880W303

     

    EXHIBIT INDEX

     

    EXHIBIT   DESCRIPTION
    I   Limited Power of Attorney*
    II   Joint Filing Agreement*
         
         

    *Previously filed

     

     

    Get the next $PHIO alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $PHIO

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $PHIO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Phio Pharmaceuticals Corp.

      SC 13G/A - Phio Pharmaceuticals Corp. (0001533040) (Subject)

      11/13/24 11:20:45 AM ET
      $PHIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Phio Pharmaceuticals Corp. (Amendment)

      SC 13G/A - Phio Pharmaceuticals Corp. (0001533040) (Subject)

      2/6/24 10:30:10 AM ET
      $PHIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Phio Pharmaceuticals Corp. (Amendment)

      SC 13G/A - Phio Pharmaceuticals Corp. (0001533040) (Subject)

      2/8/23 6:07:04 AM ET
      $PHIO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PHIO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 3 filed by new insider Deming David H

      3 - Phio Pharmaceuticals Corp. (0001533040) (Issuer)

      3/4/25 4:58:30 PM ET
      $PHIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • VP, CFO Infarinato Robert M. was granted 3,000 shares, increasing direct ownership by 38% to 11,000 units (SEC Form 4)

      4 - Phio Pharmaceuticals Corp. (0001533040) (Issuer)

      9/13/24 3:00:20 PM ET
      $PHIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Freeman Jonathan E was granted 1,000 shares (SEC Form 4)

      4 - Phio Pharmaceuticals Corp. (0001533040) (Issuer)

      9/13/24 2:59:52 PM ET
      $PHIO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PHIO
    Leadership Updates

    Live Leadership Updates

    See more
    • Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Virtual Non-Deal Roadshow Series

      Registration Link for Presentation and live Q&A to take place, Wednesday, May 7, 2025 at 2:00 pm ESTMarlborough, Massachusetts--(Newsfile Corp. - May 1, 2025) - Phio Pharmaceuticals Corp. (NASDAQ:PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio announced today that Mr. Robert Bitterman, CEO and Chairman of the Board, Phio Pharmaceuticals will present an update on the company's proprietary INTASYL siRNA technology and progress on the on-going clinical trial with lead compound PH-762 for treatment of skin cancers. Phio's presentation and live Q&A will take place on Wednesday, May

      5/1/25 7:45:00 AM ET
      $PHIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Phio Pharmaceuticals Announces Appointment of David H. Deming to Board of Directors

      Marlborough, Massachusetts--(Newsfile Corp. - February 20, 2025) - Phio Pharmaceuticals Corp. (NASDAQ:PHIO) is a clinical-stage biotechnology company developing therapeutics that use its INTASYL® siRNA gene silencing technology designed to make the body's immune cells more effective in killing cancer cells. Phio announced today the appointment of Mr. David H. Deming to the Phio Board of Directors, effective Feb 19, 2025. Mr. Deming will immediately serve as a member of the Board's Nominating Committee. Following the appointment of Mr. Deming, the Board now comprises 6 directors, 5 of whom are independent."Mr. Deming's extensive experience in in the biopharma sector, both through his investme

      2/20/25 7:45:00 AM ET
      $PHIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Phio Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update

      Marlborough, Massachusetts--(Newsfile Corp. - August 14, 2024) - Phio Pharmaceuticals Corp. (NASDAQ:PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ siRNA gene silencing technology is designed to make immune cells more effective in killing tumor cells, today reported its financial results for the quarter ended June 30, 2024 and provided a business update.Recent Corporate UpdatesThe Phase 1b clinical trial for our lead product candidate, PH-762, received a positive safety recommendation from the Safety Monitoring Committee (SMC). There were no dose-limiting toxicities, or clinically relevant treatment-emergent adverse events in the initial cohort receiving intratumora

      8/14/24 5:00:00 PM ET
      $PHIO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PHIO
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $PHIO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more

    $PHIO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $PHIO
    SEC Filings

    See more
    • Phio Pharmaceuticals Announces Positive Pathology Results in Third Cohort in INTASYL PH-762 Skin Cancer Clinical Trial

      Complete Pathologic Response reported in 2 patients in the Third Cohort with cutaneous squamous cell carcinoma, complementing results in prior cohort Phio to present trial results to date at a podium presentation at Society for Investigative Dermatology (SID) Annual Meeting on May 10thMarlborough, Massachusetts--(Newsfile Corp. - May 7, 2025) - Phio Pharmaceuticals Corp. (NASDAQ:PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio announced today that a complete pathologic response (100% tumor clearance) has been reported for 2 of 3 patients with cutaneous squamous cell carcinoma (

      5/7/25 7:45:00 AM ET
      $PHIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Virtual Non-Deal Roadshow Series

      Registration Link for Presentation and live Q&A to take place, Wednesday, May 7, 2025 at 2:00 pm ESTMarlborough, Massachusetts--(Newsfile Corp. - May 1, 2025) - Phio Pharmaceuticals Corp. (NASDAQ:PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio announced today that Mr. Robert Bitterman, CEO and Chairman of the Board, Phio Pharmaceuticals will present an update on the company's proprietary INTASYL siRNA technology and progress on the on-going clinical trial with lead compound PH-762 for treatment of skin cancers. Phio's presentation and live Q&A will take place on Wednesday, May

      5/1/25 7:45:00 AM ET
      $PHIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Phio Pharmaceuticals Announces Positive Safety Monitoring Committee Recommendation to Advance INTASYL PH-762 Skin Cancer Study to Fourth Dose Escalation Cohort

      -Phio's lead clinical siRNA compound PH-762 demonstrates supportive safety profile in third cohort, permitting escalation in next dose concentrationMarlborough, Massachusetts--(Newsfile Corp. - April 9, 2025) - Phio Pharmaceuticals Corp. (NASDAQ:PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® siRNA gene silencing technology to eliminate cancer. Phio announced today that the Safety Monitoring Committee (SMC) recommended dose escalation in Phio's Phase 1b clinical trial (NCT 06014086) for Phio's lead product candidate, PH-762.Phio's Phase 1b clinical trial is a multi-center, dose-escalating trial designed to evaluate the safety a

      4/9/25 7:45:00 AM ET
      $PHIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HC Wainwright & Co. reiterated coverage on Phio Pharmaceuticals with a new price target

      HC Wainwright & Co. reiterated coverage of Phio Pharmaceuticals with a rating of Buy and set a new price target of $6.00 from $4.00 previously

      6/14/21 6:22:20 AM ET
      $PHIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • President & CEO Bitterman Robert J bought $740 worth of shares (1,000 units at $0.74), increasing direct ownership by 5% to 20,990 units (SEC Form 4)

      4 - Phio Pharmaceuticals Corp. (0001533040) (Issuer)

      6/11/24 5:00:11 PM ET
      $PHIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • President & CEO Bitterman Robert J bought $750 worth of shares (1,000 units at $0.75), increasing direct ownership by 5% to 19,990 units (SEC Form 4)

      4 - Phio Pharmaceuticals Corp. (0001533040) (Issuer)

      6/10/24 5:00:16 PM ET
      $PHIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Bitterman Robert J bought $2,275 worth of shares (2,500 units at $0.91), increasing direct ownership by 15% to 18,990 units (SEC Form 4)

      4 - Phio Pharmaceuticals Corp. (0001533040) (Issuer)

      2/27/24 4:42:27 PM ET
      $PHIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Phio Pharmaceuticals Corp. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - Phio Pharmaceuticals Corp. (0001533040) (Filer)

      5/7/25 4:15:15 PM ET
      $PHIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Phio Pharmaceuticals Corp. filed SEC Form 8-K: Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits

      8-K - Phio Pharmaceuticals Corp. (0001533040) (Filer)

      4/22/25 4:05:09 PM ET
      $PHIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Phio Pharmaceuticals Corp. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - Phio Pharmaceuticals Corp. (0001533040) (Filer)

      4/9/25 8:20:34 AM ET
      $PHIO
      Biotechnology: Pharmaceutical Preparations
      Health Care